Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Eisai Inc., and Ipsen Pharma S.A.S.

Cancer Summaries and Commentaries™: Update from Munich: Advances in the Treatment of Gastrointestinal Cancers


Release Date: November 30, 2018
Expiration Date: November 30, 2019
Media: Internet - based

Activity Overview

This online activity updates physicians on data presented at the European Society for Medical Oncology (ESMO) meeting, held in Munich, Germany, in October 2018. PER’s Cancer Summaries and Commentaries™: Update from Munich: Advances in the Treatment of Gastrointestinal Cancers online CME activity facilitates critical assessment and, when appropriate, clinical integration of new evidence. The activity reviews 8 abstracts selected by program faculty, John Marshall, MD, and Arndt Vogel, MD, with some of the most compelling and clinically relevant GI cancer presentations from the meeting. For each abstract, a short summary of key clinical data is accompanied by expert perspectives that provide insight into how clinicians can apply these findings to their clinical practice to improve patient care.

Benefits of Participation:
  • Learn the benefits of novel treatment strategies for patients with GI cancers
  • Hear about challenging case discussions in the treatment of patients with GI cancers
  • Understand how to apply the results of recent clinical trials to your practice
  • Learn how to manage adverse events in patients with GI cancers
  • Explore future directions for patients with GI cancers with rare genetic mutations

Acknowledgement of Commercial Support

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Eisai Inc., and Ipsen Pharma S.A.S.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME certificate upon completion of these steps.


Target Audience

This educational activity is directed toward medical oncologists and fellows who treat patients with GI cancers. Gastroenterologists, surgical oncologists, radiation oncologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of GI cancers are also invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Detail the design, efficacy, and safety data presented on completed and ongoing clinical trials evaluating novel treatment strategies for GI cancers
  • Integrate recent trial results into evolving treatment paradigms for GI cancers
  • Identify planned/ongoing clinical trials intended to address unanswered clinical questions in the field of GI cancer, including agents that target rare gene mutations

Faculty, Staff, and Planners' Disclosures

Faculty

John Marshall, MD
John Marshall, MD
Chief, Division of Hematology/Oncology
Medstar Georgetown University Hospital
Director, Ruesch Center for the Cure of GI Cancers
Washington, DC
 

Disclosures: Grant/Research Support: Roche, Amgen, Bayer, Celgene, Taiho, Merck, Indivumed, Caris. Consultant: Roche, Amgen, Bayer, Celgene, Taiho, Merck, Indivumed, Caris. Speaker’s Bureau: Roche, Amgen, Bayer, Celgene, Taiho, Merck, Indivumed, Caris.

Arndt Vogel, MD, PhD
Arndt Vogel, MD, PhD
Professor of Gastrointestinal Oncology
Hannover Medical School
Hannover, Germany
 

Disclosures: Grant/Research Support: Shire. Consultant: Bayer, Roche, Lilly, MSD, Novartis, Eisai, Piere Fabre. Speaker’s Bureau: Roche, MSD, Bayer, Sanofi, Novartis, Eisai, Astra, Ipsen, Servier, Piere Fabre.

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

PER Pulse Recaps

1 of 2
Insights From John Marshall, MD, Chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, and Director, Ruesch Center for the Cure of Gastrointestinal Cancer, Washington, DC—PER Pulse™ Recap:
Cancer Summaries and Commentaries™: Update From Munich: Advances in the Treatment of Gastrointestinal Cancers

In this continuing medical education–certified activity, Cancer Summaries and Commentaries™: Update From Munich: Advances in the Treatment of Gastrointestinal Cancers, expert faculty Dr. Marshall details the design, efficacy, and safety data presented on completed and ongoing clinical trials evaluating novel treatment strategies for gastrointestinal (GI) cancers. The expert faculty integrates recent trial results into evolving treatment paradigms for GI cancers and identify planned/ongoing clinical trials intended to address unanswered clinical questions in the field of GI cancer, including agents that target rare gene mutations.

This first of 2 PER Pulse™ Recaps summarizing the online program focuses on 4 clinical trials. Below are some highlights from the activity featuring Dr. Marshall:

  • Faculty discuss the design of the phase II REGOLD trial (NCT02788006) by describing the patient population and treatment dose used for this population, as well as the possible impact of this study for the patient community, and provide an overall rationale for the use of regorafenib in an older patient population.1
  • Faculty describe the use of multi-omic molecular profiling combination therapy optimization in GI cancers and how the use of multi-omic tumor profiling impacts advance drug development and prioritization.2
  • Faculty present results of the international phase II TALENT trial (GETNE 1509) testing lenvatinib in patients with advanced pancreatic and gastrointestinal grade 1/2 (G1/G2) neuroendocrine tumors.3
  • Faculty describe the design and rationale for the use of sorafenib in patients with hepatocellular carcinoma with microvascular invasion after hepatectomy and discusses what needs to be done before making this therapeutic option a standard-of-care approach.4

“The trick to get regorafenib is not really how old the patient is, it’s what condition they are in. When you pick the right patient regardless of age, and then if you couple that [with] our improved understanding in dose and schedule, in fact, you get even better results.

“Molecular profiling is valuable not only to individual patients, but to us as a collective body doing drug development and drug discovery.”

—John Marshall, MD

References

  1. Aparicio T, Darut Jouve AD, Khemissa F, et al. Phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients (pts) over 70 with previously treated metastatic colorectal adenocarcinoma (mCRC) FFCD 1404 - REGOLD. Presented at: ESMO 2018 Congress; October 19-23, 2018; Munich, Germany. Abstract 466P.
    academic.oup.com/annonc/article/29/suppl_8/mdy281.014/5141197?searchresult=1Abstract 466P. Accessed November 26, 2018.
  2. Monge Bonilla MC, Blais E, Chen W, Pishvain M, Petricoin E, Marshall JL. Combination therapy optimization in gastrointestinal cancers using multi-omic molecular profiling. Presented at: ESMO 2018 Congress; October 19-23, 2018; Munich, Germany. Abstract 417PD.
    academic.oup.com/annonc/article/29/suppl_8/mdy279.405/5140688?searchresult=1. Accessed November 26, 2018.
  3. Capdevila J, Fazio N, Lopez C, et al. Efficacy of lenvatinib in patients with advanced pancreatic (panNETs) and gastrointestinal (giNETs) grade 1/2 (G1/G2) neuroendocrine tumors: results of the international phase II TALENT trial (GETNE 1509). Presented at: ESMO 2018 Congress; October 19-23, 2018; Munich, Germany. Abstract 1307O.
    academic.oup.com/annonc/article/29/suppl_8/mdy293/5141094?searchresult=1. Accessed November 26, 2018.
  4. Zhang Z, Huang Y, Zhou Y, Yang J, Hu K, Wang Z. Survival analysis of sorafenib in hepatocellular carcinoma patients with microvascular invasion after hepatectomy. Presented at: ESMO 2018 Congress; October 19-23, 2018; Munich, Germany. Abstract 1926P.
    academic.oup.com/annonc/article/29/suppl_8/mdy304.033/5141130?searchresult=1

2 of 2
Insights From Arndt Vogel, MD, PhD, Professor of Gastrointestinal Oncology, Hannover Medical School, Hannover, Germany—PER Pulse™ Recap:
Cancer Summaries and Commentaries™: Update From Munich: Advances in the Treatment of Gastrointestinal Cancers

In this continuing medical education–certified activity, Cancer Summaries and Commentaries™: Update From Munich: Advances in the Treatment of Gastrointestinal Cancers, expert faculty Dr. Vogel, integrates recent trial results into evolving treatment paradigms for gastrointestinal (GI) cancers and identifies planned/ongoing clinical trials intended to address unanswered clinical questions in the field of GI cancer, including agents that target rare gene mutations.

This second of 2 PER Pulse™ Recaps summarizing the online program focuses on completed and ongoing clinical trials evaluating novel treatment strategies for GI cancers. Dr.Vogel reviews the study design, results, and implications of 4 relevant clinical trials addressing the role of druggable kinase fusions in colorectal cancers for the treatment landscape, the use of atezolizumab with bevacizumab in hepatocellular carcinoma (HCC), TAS-102 versus placebo in patients with refractory metastatic gastric cancer, and the phase III CELESTIAL trial of cabozantinib versus placebo in previously treated advanced HCC.

Below are some highlights from the activity featuring Dr. Vogel:

  • Dr. Vogel describes the rationale for the use of kinase rearrangements in colorectal cancer and provides insight into the patient population who may benefit from both tyrosine kinase inhibitors and checkpoint inhibitors, either as respective monotherapies or in combination.1
  • Dr. Vogel discusses the use of atezolizumab plus bevacizumab in patients with HCC, providing his thoughts on the overall benefits of the use of this combination for patients with HCC.2
  • Dr. Vogel describes the benefits of TAS-102 in patients with refractory metastatic gastric cancer.3
  • Dr. Vogel describes the design and rationale for the study of cabozantinib in patients with previously treated advanced HCC and provides the main findings and the toxicity profile of the treatment.4

References

  1. Madison R, Pietrantonio F, Juckett L, et al. Kinase fusions in colorectal cancers: a unique biologic subset. Presented at: ESMO 2018 Congress; October 19-23, 2018; Munich, Germany. Abstract 457PD.
    academic.oup.com/annonc/article/29/suppl_8/mdy281.005/5141111?searchresult=1. Accessed November 26, 2018.
  2. Pishvaian MJ, Lee MS, Ryoo B-Y, et al. Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC). Presented at: ESMO 2018 Congress; October 19-23, 2018; Munich, Germany. Abstract LBA26.
    academic.oup.com/annonc/article/29/suppl_8/mdy424.028/5141676?searchresult=1. Accessed November 26, 2018.
  3. Arkenau H-T, Tabernero J, Shitara K, et al. TAGS: a phase III, randomised, double-blind study of trifluridine/tipiracil (TAS-102) versus placebo in patients with refractory metastatic gastric cancer. Presented at: ESMO 2018 Congress; October 19-23, 2018; Munich, Germany. Abstract LBA25.
    academic.oup.com/annonc/article/29/suppl_8/mdy424.027/5141669?searchresult=1. Accessed November 26, 2018.
  4. Kelley RK, El-Khoueiry AB, Meyer T, et al. Outcomes by baseline alpha-fetoprotein (AFP) levels in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (HCC). Presented at: ESMO 2018 Congress; October 19-23, 2018; Munich, Germany. Abstract 702P.
    academic.oup.com/annonc/article/29/suppl_8/mdy282.085/5141440?searchresult=1.

“We are entering the time of precision oncology, which means we can identify patients based on genetic or genomic rearrangements and apply specific targeted therapies, and to do that, we need to identify patients who have these druggable alterations.”

— Arndt Vogel, MD, PhD


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
24252627282930
Filter By